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Introduction: Although the use of computerized decision support systems (CDSS) in glucose
control  in the ICU has been reported, little is known about the effect of the systems’ operating
modes  on the quality of glucose control. The objective of this study was to evaluate the
effect  of providing patient-speciﬁc and patient non-speciﬁc computerized advice on timing
of  blood glucose level (BGL) measurements. Our hypothesis was that both levels of support
would  be effective for improving the quality of glucose regulation and safety, with patient
speciﬁc  advice being the most effective strategy.
Patients and methods: A prospective study was performed in a 30-bed mixed medical-surgical
intensive  care unit (ICU) of a university hospital. In phase 1 the CDSS provided non-speciﬁc
advice  and thereafter, in phase 2, the system provided speciﬁc advice on timing of BGL
measurements.  The primary outcome measure was delay in BGL measurements before and
after the two levels of support. Secondary endpoints were sampling frequency, mean BGL,
BGL  within pre-deﬁned targets, time to capture target, incidences of severe hypoglycemia
and  hyperglycemia. These indicators were analyzed over the course of time using Statisti-
cal  Control Charts. The analysis was restricted to patients with at least two blood glucose
measurements.
Results:  Data of 3934 patient admissions were evaluated, which corresponded to 119,116
BGL  measurements. The BGL sampling interval, delays in BG sampling, and percentage ofhypoglycemia all decreased after introducing either of the two levels of decision support. The
effect was however larger for the patient speciﬁc CDSS. Mean BGL, time to capture target,
hyperglycemia  index, percentage of hyperglycemia events and “in range” measurements
remained  unchanged and stable after introducing both patient non-speciﬁc and patient
speciﬁc  decision support.∗ Corresponding author. Tel.: +31 20 5666252.
E-mail address: s.eslami@amc.uva.nl (S. Eslami).
386-5056  © 2011 Elsevier Ireland Ltd. 
oi:10.1016/j.ijmedinf.2011.10.004
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54  i n t e r n a t i o n a l j o u r n a l o f m e d i c a l i n f o r m a t i c s 8 1 ( 2 0 1 2 ) 53–60
Adherence to protocol sampling rules increased by using decision support with a larger
effect  at the patient speciﬁc level. This led to a decrease in the percentage of hypoglycemia
events  and improved safety. The use of the CDSS at both levels, however, did not improve
the  quality of glucose control as measured by our indicators. More  research is needed to
investigate  whether other socio-technical factors are in play.
A local ICU database identiﬁed all patients admitted to the ICU.
The hospital information system and PDMS were  searched for
Table 1 – Protocol characteristics.
Type of protocol Sliding scales
Present in what form Written
Who is responsible for glucose control
Start  of insulin By nurse
Dosing of insulin By nurse
Correction of hypoglycemia By nurse
Protocol thresholds and targets
Start  of insulin (mg/dL) >144
BGL targets (mg/dL) 90–144
Timing of BGL-measurements
described in or mandated by the
protocol
Yes
Rules  on stopping insulin
Threshold  to stop insulin infusion <63 or 63–144 with > 50%
reduction of BGL
Other reason for stopping insulin Stop of feeding
Action in case of hypoglycemia
BGL  < 40 mg/dL 50 ml 20% glucose1.  Introduction
Studies have shown that critically ill patients could beneﬁt
from  blood glucose regulation during their stay in the inten-
sive  care unit (ICU) [1,2]. Recent studies have shown that
frequent  and timely BGL measurements improved the quality
and  safety of blood glucose regulation [3,4]. Continuous blood
glucose  monitoring would have provided timely measurement
of  blood glucose, but devices to do this are expensive and are
not  commonly available yet.
Clinical computerized decision support systems (CDSS) are
computer  programs  that are intended to help healthcare work-
ers  in making decisions [5]. A CDSS can be characterized by
the  level of support. The level of decision support varies from
non-patient  speciﬁc (general support) to patient speciﬁc sup-
port.  For the purpose of this study, non-patient speciﬁc CDSS
is  deﬁned as showing the protocol without interpreting the
patient’s  data. On the other hand, patient speciﬁc CDSS refers
to  making a conclusion or giving advice after interpreting the
patient’s  data. The difference between the effects of these lev-
els  of support has not been studied yet, at least not in this
domain.
ICU  staff increasingly use patient data management sys-
tems  (PDMS) allowing them to access data, but these systems
often  do not provide active support for making decisions.
Based on the literature and our recent systematic reviews
[6,7]  we  hypothesized that both levels of support, patient
non-speciﬁc as well as patient speciﬁc, would increase the
adherence  to protocol sampling rules in terms of reducing
blood  glucose sampling delays, and that the patient speciﬁc
support  would give better results. The underlying idea is that
improving  adherence to the protocol leads to improving qual-
ity  and safety of glucose regulation. The purpose of this study
was  to test this hypothesis and measure the effect of the two
different  levels of support, patient non-speciﬁc and patient
speciﬁc  support, embedded in a PDMS, on adherence to sam-
pling  rules of a locally developed glucose regulation protocol.
2. Methods
2.1. Study location
Collection of data was  prospectively performed in a 30-bed
“closed-format” mixed medical-surgical ICU of an academic
hospital in the Netherlands. For each patient there was one
ICU  nurse who  stayed near to the patient bed. The ICU uses
a  patient data management system (PDMS) (Metavision,
ImdSoft Sassenheim, the Netherlands) since March 2002.
There  is a bedside computer available for each bed. The
ICU  teams used the PDMS to complete all patient charting© 2011 Elsevier Ireland Ltd.     
and  documentation such that no information had paper as
its  primary storage mechanism. The laboratory computer
interface conveyed BGL measurement results to the PDMS.
Consequently, the PDMS processes and displays all values
directly  after their measurement with a maximum delay of
1  min, introduced by the interface.
2.2.  Local  glucose  control  protocols
Table 1 shows the protocol’s characteristics. According to the
protocol  when the latest BGL is in the normal range it should
be  rechecked after 4 h. When the latest BGL is out of the
pre-deﬁned range it should be generally rechecked after 1 h.
When  the latest BGL is in a hypoglycemic range it should be
rechecked  after 30 min.
2.3.  Measurement  of  BGL
Arterial blood samples were used for BGL measurements.
These measurements were  obtained by blood gas analyzers
(Rapidlab 865®, Bayer, Germany) in the ICU and a glucose
analyzer (Modular P800® system, Roche Diagnostics GmbH,
Germany) in the hospital’s central laboratory.
2.4.  Patients
Open access under the Elsevier OA license.The term “sliding scale” here refers to a dynamic protocol for
intravenous insulin infusion. The protocol is self-regulating, there-
fore it does not consider baseline glucose value nor condition (e.g.
diabetes).
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Table 2 – Outcome measures description.
Protocol related indicators (primary outcome measures)
Sampling frequency Represented as the mean sampling
interval
Delay in blood glucose
monitoring
Represented as the mean delay time.
When the next measurement was done
earlier than 10 min before the scheduled
time, delay time was considered −10
Safety-related indicators
Hypoglycemia Reported as percentage of overall BGL
measurements ≤40 mg/dl (severe) and
≤63 mg/dl (moderate) and as percentage
of patients with at least 1 episode of
(severe) hypoglycemia. After a
hypoglycemic event, to classify a
subsequent BGL measurement as starting
a new hypoglycemic event we require
that the BGL ﬁrst increase into the normal
range and then drop again below the
hypoglycemia threshold in a subsequent
hour
Hyperglycemia Deﬁned as BGL > 144 mg/dl, and severe
hyperglycemia as BGL >180 mg/dl. These
are reported as the percentage of overall
BGL measurements above the given
threshold
Hyperglycemia index The area between the BGL curve and the
144 mg/dl (hyperglycemia) threshold
divided by time. We report on the mean of
this value per patient
Effectiveness/efﬁciency-related indicators
Mean BGL The overall mean BGL during a deﬁned
time interval (more focus on efﬁciency
can be obtained by shortening thei n t e r n a t i o n a l j o u r n a l o f m e d i
ll records on BGL. The ﬁrst BGL measured directly after ICU
dmittance was excluded from the ﬁnal analysis for further
alculation, because they are hardly inﬂuenced by any ICU reg-
men. Admitted patients who had in total more  than two BGL
easurements, including admission BGL, were included in the
nal analysis.
.5. Intervention
he intervention was carried out in three phases.
The glucose regulation protocol was implemented in early
002 and was last revised in 2005 [8].  This nurse-driven proto-
ol was in use and available on both paper and the hospital
ntranet in 2002. In phase 0 in this study the glucose con-
rol protocol was still only available on paper and the hospital
ntranet. In this phase, lasting for 8 months, we prospectively
ollected the data that formed the baseline for the consequent
hases.
In phase 1 of the study a patient non-speciﬁc CDSS was
sed for 8 months. Every 5 min  the system checked for new
GL measurements. Only when there was a new BGL measure-
ent the CDSS showed a snapshot of the protocol in a pop-up
indow. This non-speciﬁc reminder appeared only if the ICU
urse was logged in at the bedside computer and worked in
he PDMS. The pop-up window showed the whole BGL protocol
ncluding the general timing and pump position advice.
In phase 2, with duration of 10 months, the CDSS also
hecked for new BGL measurements every 5 min. When a new
GL measurement was encountered the CDSS calculated the
ime for the next measurement according to the protocol and
he patient’s former BGLs. The time for the next expected mea-
urement was then recorded in a database. The CDSS gave
 reminder about 10 min  before the next expected measure-
ent was due. The pop-up window showed the planned time
f measurement and reminded the ICU nurse to measure the
GL and to follow the protocol. The system showed a message
nly if the expected BGL was not timely performed and only
f the ICU nurse was logged in at the bedside computer and
orked with the PDMS.
.6.  Outcome  measures
elay in blood glucose monitoring was the primary out-
ome measure. Other common performance indicators were
elected as secondary outcome measures to show the qual-
ty of glucose regulation [9].  These indicators are described in
able 2.
.7. Statistical  process  control  (SPC)
PC uses statistical methods to identify periods of time dur-
ng which a process goes from “in control” to “out of control.”
PC and its primary tool – the control chart – are a branch of
tatistics that combines rigorous time series analysis meth-
ds with graphical data presentation, often yielding insights
nto the data more  quickly and in a more  understandable way
han other statistical techniques [10]. Control charts can dis-
inguish between common and special causes of variation [11].
ith common cause variation (noise), the variation is inherent
n the process itself and the process is stable and predictableinterval)
within certain limits. Special cause variation signiﬁes that the
process is no longer stable or predictable and has changed
(either for better or worse) [12]. A control chart includes a plot
of the data over time with three additional lines – the center
line (usually reﬂecting the mean) and an upper and lower con-
trol limits, typically set at ±3 sigma from the mean. When the
data points are, without any special pattern, within the con-
trol limits then the process is “in control” and stable. There
are several rules that indicate when a special cause variation
or a special pattern has occurred on a control chart. We used
the following four widely used rules to identify a special cause
variation: one or more  points beyond a control limit, a run of
seven or more  points on one side of the center line, two  out
of three consecutive points appearing beyond 2 sigma on the
same side of the center line, or a run of seven or more  points
all trending up or down.
2.8.  Power  analysis
Previous studies have shown that CDSS could reduce delay in
measurement by about 50% [13]. Power analysis showed that
at least 2000 BGL measurements were needed to demonstrate
an absolute difference of 25% in delay time between baseline
and the most effective intervention, with an alpha of 0.05 and
beta of 0.8. Retrospective data analysis showed that at least 2
weeks of data would be needed to meet these requirements.
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Table 3 – Patient characteristics.
Variable Phase 0 Patient non-speciﬁc CDSS Patient speciﬁc CDSS p-Value
Number 1014 1017 1470
Age (years) 60 ± 15.5 60 ± 15.8 61 ± 15.9 0.62
Male (%) 36% 36% 36% 0.91
APACHE II 19.6 ± 7.8 21.1 ± 7.8* 20.6 ± 7.6* <0.01
Surgical 62% 60% 57% 0.09
ICU LOS (day) 4.9 ± 7.9 4.6 ± 6.8 4.4  ± 7.5 0.25
ICU mortality (%) 12% 11%  11% 0.73
Admission BGL 8.4 ± 4.5 8.4 ± 4.6 8.2 ± 4.1 0.70
All data are mean ± SD (medians).
∗ Phase 0 and patient non-speciﬁc; phase 0 and patient speciﬁc.
2.9.  Statistical  analysis
We  used the X-MR control chart [11] to plot and analyze the
processes. We  used the X-MR chart instead of attribute charts
[14,15] due to the large subgroup size and hence the increased
chance of false positive results. The quality indicators that
we choose (each represents either a mean or a proportion)
were calculated per month and plotted as points on the X-MR
chart. The mean of the points before glucose control imple-
mentation was calculated along with the ±3 sigma limits. To
determine whether a change in the process occurs further
along the time axis, the mean and control limits, as calcu-
lated based on the 8 months of phase 0, were extrapolated
over the entire study period. The ANOVA, Kruskal–Wallis and
Chi square tests were used to assess the statistical signiﬁcance
Fig. 1 – Control charts of mean BGL sampling intervals and delay
September 2008 (introducing of phase II) and according to SPC ru
line) all processes became out of control (here corresponding to a
limits (UCL) and lower control limits (LCL) were  calculated based
entire study period.of differences among pre- and post-intervention periods and
to compare these results with those of the SPC analysis. All
analysis was performed with Systat 12.
3.  Results
3.1.  Patients
In total, data of 3934 patient admissions (from 01 May 2007
to 30 June 2009) were evaluated, corresponding to 119,116
BGL measurements prospectively. Table 3 shows the patient
baseline characteristics. Only the APACHE II score showed a
statistically signiﬁcant higher value in the intervention period
compared to the “before” period.
 in BG monitoring (protocol-related indicator). Since
les (run of seven or more  points on one side of the center
 signiﬁcant reduction). The center lines (CL), upper control
 on the ﬁrst 8 months (phase 0) and extrapolated over the
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.2.  CDSS  messages
n the two intervention periods, the message was shown
1,875 times: 18,190 times in the patient non-speciﬁc phase
nd 23,685 times in the patient speciﬁc phase.
.3.  Protocol  related  indicators
verall adherence to the part of the protocol concerning
iming of measurements increased signiﬁcantly. Mean inter-
al between BGL measurements decreased signiﬁcantly after
ntroducing the CDSS in both levels of support (Table 4 and
ig. 1). However the reduction of the interval was larger when
atient speciﬁc decision support was provided. The other
rotocol related indicator, delay in blood glucose monitor-
ng, decreased and became “out of control,” according to SPC
ules, after CDSS introduction in both speciﬁc and non-speciﬁc
hases. Becoming “out of control” means that a signiﬁcant
hange has been detected. Because this change is related to
 decrease in the delay time, this is a good change signify-
ng improvement. The reduction in the glucose measurement
nterval was greater in the BGL measurements that were high
hyperglycemic) and that were within target range (Fig. 1), in
omparison to the measurements that were below the target
ange (hypoglycemic). This reduction was also signiﬁcantly
reater in the patient speciﬁc phase than in the patient non-
peciﬁc phase.
.4.  Safety  of  glucose  control
ontrol charts of safety-related quality indicators are shown
n Figs. 2 and 3 (hypoglycemia, hyperglycemia, and hyper-
lycemic index). The percentage of hyperglycemia and
yperglycemic indices did not change after any of the inter-
entions. The percentage of BGL measurements that were
40 mg/dl (severe hypoglycemia) and ≤65 mg/dl (moderate
ypoglycemia) decreased after implementation of the patient
peciﬁc CDSS (Fig. 2). According to SPC rules, this reduction
as statistically signiﬁcant for moderate hypoglycemia.
.5.  Effectiveness  and  efﬁciency  of  glucose  control
ig. 4 shows the quality control charts for the
ffectiveness/efﬁciency-related indicators of glucose con-
rol. Mean BGL, the percentage of BGL within locally deﬁned
argets, and time to reach targets did not change after
ntroducing the patient non-speciﬁc and patient speciﬁc
DSS.
The results of ANOVA, Kruskal–Wallis and chi square
ests on the effect of introducing glucose control and related
hanges on these indicators were concordant with the SPC
esults (Table 4).
. Discussionn this study we showed that a CDSS, integrated in a PDMS in
oth patient speciﬁc and patient non-speciﬁc levels, improved
dherence to a locally developed protocol for BGL regulation
n terms of reducing blood glucose monitoring delay in ICU
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Fig. 2 – Control charts of percentage BGL ≤40 mg/dl and
≤63 mg/dl (safety-related indicators), shown respectively at
the bottom and top of the ﬁgure. Since April 2009 (marked
by * in the chart at the top) and according to the SPC rules
(one point beyond lower control limit and two out of three
consecutive points beyond 2 sigma on the same side of
control line) the percentage of moderate hypoglycemia
signiﬁcantly reduced and the process became out of
control. However, although severe hypoglycemia
demonstrated reduction this was not detectable by SPC
rules as a signiﬁcant one. The center lines (CL), upper
control limits (UCL) and lower control limits (LCL) were
calculated based on the ﬁrst 8 months (phase 0) and
extrapolated over the entire study period.
Fig. 3 – Control charts of mean hyperglycemia index and
percentage of BGL > 144 mg/dl (safety-related indicators),
shown respectively at the bottom and top of the ﬁgure.
According to SPC rules all processes are stable and in
control (i.e. there are no signiﬁcant changes detected). The
center lines (CL), upper control limits (UCL) and lower
control limits (LCL) were  calculated based on the ﬁrst 8
months (phase 0) and extrapolated over the entire studypatients. However, the effect was greater in the patient spe-
ciﬁc CDSS. Interestingly, the improvement in adherence to
protocol sampling rules did not lead to improvement in the
quality of BGL regulation. We  found a slight improvement in
the safety aspect of BGL regulation only for the CDSS with
patient-speciﬁc advice, with a decrease in the percentage of
moderate hypoglycemic events.
Recent studies [3,4] showed that when BGL measurement is
performed frequently and on time then the quality and safety
of glucose regulation improve. There are several reasons for
delays in glucose monitoring, and forgetting to perform a test
is the most important one. A computerized reminder system,
like the one which we  developed and implemented, could beperiod.
useful. There are several evaluation studies on the effect of
CDSS on BGL regulation [6].  In contrast to the majority of the
published studies in this ﬁeld, we used an active CDSS, mean-
ing that it takes the initiative to act, and it was integrated in
the daily workﬂow of nurses. In our study the glucose regu-
lation protocol was available on paper and in use for a long
time before we  implemented the CDSS. Other studies imple-
mented a BGL regulation protocol and CDSS simultaneously
which makes it hard to isolate the effect of the system alone
[16]. In addition, to our knowledge, this is the ﬁrst study that
aimed to implement a protocol on sampling rules and com-
pare two levels of support.
The CDSS used in the present study comprised of a patient
non-speciﬁc active system, which is only aware of the protocol
but does not interpret the patient’s data, and a patient-speciﬁc
active system. Developing and integrating a patient speciﬁc
CDSS is more  complicated and technically demanding than
a patient non-speciﬁc CDSS. Therefore, if they were equally
i n t e r n a t i o n a l j o u r n a l o f m e d i c a l 
Fig. 4 – Control charts, from bottom to top, of percentage of
BGLs in protocol’s range, time to reach target range, and
mean BGL (efﬁciency-related indicators). According to SPC
rules all processes are stable and in control (no signiﬁcant
change was detected). The center lines (CL), upper control
limits (UCL) and lower control limits (LCL) were calculated
based on the ﬁrst 8 months (phase 0) and extrapolated over
t
e
p
s
i
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Authors’  contributionshe entire study period.
ffective, the patient non-speciﬁc style would seem to be more
ractical and generalizable. A potential advantage of patient
peciﬁc systems, however, is that the users do not need to
nterpret the protocol and make the mental calculations them-
elves, as the CDSS does this instead. This is easier and lessi n f o r m a t i c s 8 1 ( 2 0 1 2 ) 53–60 59
time consuming for the clinicians and might increase the
acceptance of the system by healthcare workers, thus increas-
ing the effect of the CDSS.
In this study, the CDSS is triggered by a time-event (every
5 min) thereby assuring that for all new BGL measurements the
time of next measurement is calculated in a timely manner.
This also means that the reminder appears with a maxi-
mum delay of 5 min  from the desired launching time (which
is 10 min  before due time of a measurement).
Delay in blood glucose monitoring signiﬁcantly decreased
after CDSS introduction. This reduction was larger in the
higher (hyperglycemic) and in the target range measurements
than the measurements below the range (hypoglycemic). This
means that after CDSS implementation, when the BGL was
above or in the target range, the nurses performed the next
BGL measurement with less delay according to the protocol.
The frequency of measurements increased and the delay in
blood glucose monitoring decreased but the quality of glucose
regulation did not change according to the indicators used.
Only a slight improvement was shown in moderate hypo-
glycemia events. This ﬁnding could be explained in different
ways. First we note that according to the protocol, the qual-
ity of glucose regulation was already in acceptable range in
our patients before using the CDSS. Hence it is fair to hypoth-
esize that the effect of a CDSS in situations where quality
of glucose regulation is worse could be much higher than in
our patients. Second, the system is just one part of a wider
socio-technical environment where it interacts with people
[17]. Factors such as trust of nurses in the protocol may explain
why quality of BG regulation did not improve. It could be the
case that despite increasing the BGL measurement frequency,
the nurses did not adjust the insulin pump accordingly. Third,
external factors such as published negative studies [18] and
meta-analysis studies [19,20] showing no beneﬁt of tight gly-
caemic regulation could have indirectly affected the behavior
of the nurses.
A  limitation of our study is that we did not investigate if the
use of this CDSS has any inﬂuence on insulin administration
nor clinically relevant endpoints such as survival, length of
stay and costs of treatment. However, as glucose regulation
is shown to be an evidence based strategy that may decrease
mortality, adherence to this strategy is commonly advocated.
5. Conclusion
Adherence to protocol sampling rules increased with the use
of decision support, with a larger effect using patient-speciﬁc
decision support. This led to a decrease in the percentage
of hypoglycemia events and improved safety. The use of the
CDSS at both levels, however, did not improve the quality of
glucose control as measured by our indicators. More  research
is needed to investigate whether other socio-technical factors
are in play.All authors made substantial contributions to the study design
and methods. Saeid Eslami extracted data and analyzed data
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Summary points
What is already known:
• CDSSs have been identiﬁed as key for improving
patient’s safety and outcomes.
• CDSSs can increase adherence to the guidelines.
What this study added to our knowledge:
• A CDSS integrated in a patient data management sys-
tem in both levels, patient non-speciﬁc and patient
speciﬁc, improved adherence to protocol with a larger
effect at the patient speciﬁc level.
• The use of the CDSS at both levels, however, did not
improve the quality of care as measured by our indi-
cators. More  research is needed to investigate whether
socio-technical factors are at play.
• Statistical process control is a useful tool for
monitoring the effect over time and captures within-
institution signiﬁcant and stable changes.
rand drafted the manuscript. All authors interpreted the results
and were involved in revising the ﬁnal manuscript.
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